Zai Lab Ltd Asset Resilience Ratio
Zai Lab Ltd asset resilience ratio. Zai Lab Ltd (ZLAB) has an Asset Resilience Ratio of 0.93% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Zai Lab Ltd (ZLAB) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Zai Lab Ltd (2018–2025)
Asset resilience ratio of Zai Lab Ltd from 2018 to 2025. This chart shows how Zai Lab Ltd's Asset Resilience Ratio has changed over time. Read ZLAB liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Zai Lab Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Zai Lab Ltd asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $10.00 Million | 0.93% |
| Total Liquid Assets | $10.00 Million | 0.93% |
Asset Resilience Insights
- Limited Liquidity: Zai Lab Ltd maintains only 0.93% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Zai Lab Ltd Industry Peers by Asset Resilience Ratio
Compare Zai Lab Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Zai Lab Ltd Asset Resilience Ratio by Year (2018–2025)
Zai Lab Ltd asset resilience ratio by year from 2018 to 2025. The table below shows the annual Asset Resilience Ratio data for Zai Lab Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.85% | $10.00 Million | $1.17 Billion | -26.98pp |
| 2024-12-31 | 27.83% | $330.00 Million | $1.19 Billion | +26.26pp |
| 2023-12-31 | 1.57% | $16.30 Million | $1.04 Billion | -- |
| 2022-12-31 | 0.00% | $0.00 | $1.22 Billion | -- |
| 2021-12-31 | 27.64% | $445.00 Million | $1.61 Billion | -29.75pp |
| 2020-12-31 | 57.39% | $744.68 Million | $1.30 Billion | +1.07pp |
| 2019-12-31 | 56.31% | $200.00 Million | $355.15 Million | -10.03pp |
| 2018-12-31 | 66.34% | $200.35 Million | $301.99 Million | -- |
About Zai Lab Ltd
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for … Read more